FONT-SIZE Plus   Neg

Theravance, Clinigen Ink Commercialization Agreement In EU For VIBATIV

Clinigen Group plc (CLIN.L) and Theravance Inc. (THRX) have reached an exclusive commercialization agreement in the European Union or EU and certain other countries in Europe for VIBATIV to treat nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus or MRSA when other alternatives are not suitable.

VIBATIV is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as MRSA.

According to the deal, Theravance has granted Clinigen exclusive commercialization rights to VIBATIV in the EU and some other European countries, including Switzerland and Norway. Theravance, in turn, would receive a $5 million upfront payment from Clinigen and is entitled to receive tiered royalties on net sales of VIBATIV, ranging from 20% to 30%. The agreement has a term of at least 15 years, with an option to extend exercisable by Clinigen.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Buick, Lexus and Toyota are among the top brands with highest reliability rating in the latest annual brand reliability survey. A New York woman has filed a $20 million lawsuit against Kentucky Fried Chicken, accusing the fast-food giant of 'false and deceptive trade practice' and also of misleading customers as she did not get enough chicken in her $20 "Fill-Up." Fans of Girl Scouts Cookies can rejoice. General Mills Inc. has confirmed its plans to launch two cereals inspired by Girl Scout cookies next year. The cereals will come in two flavors and in boxes carrying the Girl Scouts logo.
comments powered by Disqus
Follow RTT